Genmab A/S ADR (GMAB) Social Stream



Genmab A/S ADR (GMAB): $38.52

-0.41 (-1.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GMAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

GENMAB A (GMAB) Price Targets From Analysts

Use the tables below to see what analysts covering GENMAB A think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-11 6 $50 $37 $44.8 $38.53 16.27%
2021-11-15 7 $50 $37 $44.7 $38.53 16.01%
2022-01-18 8 $50 $37 $44.7 $38.53 16.01%
2022-01-31 8 $50 $37 $44.7 $38.53 16.01%
2022-02-28 8 $50 $37 $42.2 $38.53 9.53%
2022-04-07 8 $50 $33 $41.4 $38.53 7.45%
2022-04-11 9 $50 $33 $41.416 $38.53 7.49%
2022-04-21 9 $50 $30 $40.916 $38.53 6.19%
2022-05-02 10 $50 $30 $40.5 $38.53 5.11%
2022-05-12 10 $50 $30 $38.571 $38.53 0.11%
2022-05-13 10 $50 $30 $37.9 $38.53 -1.64%
2022-06-05 10 $50 $29 $37.757 $38.53 -2.01%
2022-07-20 11 $53 $29 $38.003 $38.53 -1.37%
2022-08-13 11 $53 $29 $38.441 $38.53 -0.23%
2022-08-15 11 $53 $31 $38.691 $38.53 0.42%
2022-08-25 11 $53 $31 $38.941 $38.53 1.07%
2022-10-19 11 $53 $31 $39.316 $38.53 2.04%
2022-11-10 12 $53 $31 $39.753 $38.53 3.17%
2022-11-14 12 $53 $33 $40.128 $38.53 4.15%
2022-12-03 13 $53 $33 $40.753 $38.53 5.77%
2023-01-03 13 $53 $33 $42.091 $38.53 9.24%
2023-01-26 13 $53 $33 $42.653 $38.53 10.7%

The Trend in the Analyst Price Target


GMAB's average price target has moved up $1.25 over the prior 42 weeks.

Over the past 51 weeks, GMAB's average upside potential has been 8.51%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-02-28 8 50 37 42.200 33.46 26.12%
2022-04-21 9 50 30 40.916 37.48 9.17%
2022-05-18 10 50 29 37.757 29.59 27.6%
2022-09-17 11 53 31 39.316 36.46 7.83%
2022-11-14 12 53 33 40.128 42.54 -5.67%

GMAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.59 4 0 7 1 1 13

The Trend in the Broker Recommendations


Over the past 36 months, GMAB's average broker recommendation rating worsened by 0.87.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • GMAB has a higher upside potential (average analyst target price relative to current price) than 553.02% of all US stocks.
  • GENMAB A's average analyst price target is greater than 586.84% of stocks in the large market cap category.
  • In the context of Pharmaceutical Products stocks, GENMAB A's number of analysts covering the stock is higher than 1930.58% of them.
  • GMAB has a lower variance in analysts' estimates than -752.23% of Pharmaceutical Products stocks.

In the Pharmaceutical Products industry, ELAN, ZLAB, and RDY are the three stocks most similar to GENMAB A regarding the price target and analyst recommendation information presented here.

Is GMAB a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6583 seconds.